Abstract:Current treatments for inflammatory bowel disease (IBD) are often inadequate due to limited efficacy and toxicity, leading to surgical resection in refractory cases. IBD's broad and complex pathogenesis involving the immune system, enteric nervous system, microbiome, and oxidative stress requires more effective therapeutic strategies. In this study, we investigated the therapeutic potential of bone marrow-derived mesenchymal stem cell (BM-MSC) treatments in spontaneous chronic colitis using the Winnie mouse model which closely replicates the presentation and inflammatory profile of ulcerative colitis. The 14-day BM-MSC treatment regimen reduced the severity of colitis, leading to the attenuation of diarrheal symptoms and recovery in body mass. Morphological and histological abnormalities in the colon were also alleviated. Transcriptomic analysis demonstrated that BM-MSC treatment led to alterations in gene expression profiles primarily downregulating genes related to inflammation, including pro-inflammatory cytokines, chemokines and other biomarkers of inflammation. Further evaluation of immune cell populations using immunohistochemistry revealed a reduction in leukocyte infiltration upon BM-MSC treatment. Notably, enteric neuronal gene signatures were the most impacted by BM-MSC treatment, which correlated with the restoration of neuronal density in the myenteric ganglia. Moreover, BM-MSCs exhibited neuroprotective effects against oxidative stress-induced neuronal loss through antioxidant mechanisms, including the reduction of mitochondrial-derived superoxide and attenuation of oxidative stress-induced HMGB1 translocation, potentially relying on MSC-derived SOD1. These findings suggest that BM-MSCs hold promise as a therapeutic intervention to mitigate chronic colitis by exerting anti-inflammatory effects and protecting the enteric nervous system from oxidative stress-induced damage.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the deficiencies in the current treatment of inflammatory bowel disease (IBD), especially ulcerative colitis (UC) and Crohn's disease (CD). Due to the limited efficacy and toxicity problems of the existing treatment methods, surgical resection of the affected intestinal parts is required in refractory cases. The pathological mechanism of IBD is complex, involving multiple aspects such as the immune system, enteric nervous system (ENS), microbiome and oxidative stress, so more effective treatment strategies are needed. To meet this challenge, the research team used bone marrow - derived mesenchymal stem cells (BM - MSCs) to treat a mouse model of spontaneous chronic colitis (Winnie mice), which is highly similar to the clinical manifestations and inflammatory characteristics of UC. The main objective of the study was to evaluate the therapeutic potential of BM - MSCs in alleviating chronic colitis symptoms, anti - inflammation and anti - oxidative stress. Specifically, the study found that: 1. **Alleviating chronic colitis symptoms**: 14 - day BM - MSCs treatment significantly alleviated the diarrhea symptoms of Winnie mice and promoted weight recovery. 2. **Improving colonic morphological and histological abnormalities**: BM - MSCs treatment relieved the morphological and histological abnormalities of the colon. 3. **Gene expression changes**: Transcriptome analysis showed that BM - MSCs treatment mainly down - regulated the expression of genes related to inflammation, including pro - inflammatory cytokines, chemokines and other inflammatory markers. 4. **Reducing immune cell infiltration**: Immunohistochemical analysis showed that BM - MSCs treatment reduced leukocyte infiltration. 5. **Protecting the enteric nervous system**: BM - MSCs treatment had the greatest impact on the enteric neuron gene signature, which was related to the restoration of the neuronal density of the submucosal ganglia. 6. **Anti - oxidative stress**: BM - MSCs protect neurons from oxidative stress - induced damage through antioxidant mechanisms, including reducing mitochondrion - derived superoxide anions (\(\text{O}_2^-\)) and inhibiting oxidative stress - induced HMGB1 translocation, which may depend on SOD1 secreted by MSCs. These findings indicate that BM - MSCs have potential therapeutic value in alleviating chronic colitis symptoms, anti - inflammation and protecting the enteric nervous system from oxidative stress damage.

Bone marrow-derived mesenchymal stem cells mitigate chronic colitis and enteric neuropathy via anti-inflammatory and anti-oxidative mechanisms